Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
Chinese Patent Office
Baxter
Harvard Business School
Novartis
Teva
AstraZeneca
McKesson
Accenture

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,808,713

« Back to Dashboard

Which drugs does patent 8,808,713 protect, and when does it expire?


Patent 8,808,713 protects BEVESPI AEROSPHERE and is included in one NDA.

This patent has eighty-seven patent family members in twenty-six countries.

Summary for Patent: 8,808,713

Title:Compositions for pulmonary delivery of long-acting .beta..sub.2 adrenergic receptor agonists and associated methods and systems
Abstract: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting .beta..sub.2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Inventor(s): Vehring; Reinhard (Edmonton, CA), Hartman; Michael Steven (Millbrae, CA), Smith; Adrian Edward (Emerald Hills, CA), Joshi; Vidya B. (Redwood City, CA), Dwivedi; Sarvajna Kumar (Redwood City, CA)
Assignee: Pearl Thereapeutics, Inc. (Redwood City, CA)
Application Number:12/790,605
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION208294-001Apr 25, 2016RXYesYes► Subscribe► SubscribeY USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,808,713

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,463,161Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems► Subscribe
8,324,266Compositions, methods and systems for respiratory delivery of two or more active agents► Subscribe
8,815,258Compositions, methods and systems for respiratory delivery of two or more active agents► Subscribe
9,415,009Compositions, methods and systems for respiratory delivery of two or more active agents► Subscribe
8,703,806Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,808,713

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan5823383► Subscribe
China102596176► Subscribe
China102753152► Subscribe
China105193773► Subscribe
Cyprus1118030► Subscribe
Cyprus1118034► Subscribe
Cyprus1118040► Subscribe
Denmark2435023► Subscribe
Denmark2435024► Subscribe
Denmark2435025► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Harvard Business School
Merck
McKinsey
Farmers Insurance
Deloitte
Johnson and Johnson
Express Scripts
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot